Healthcare News and Headlines
Healthcare News and Headlines
Healthcare Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that alleviate inflammatory and neuropathic pain in rodent studies and are slated for IND‑enabling toxicology this year, aiming for Phase I trials in 2027. Parallel research highlights chronic inflammation’s role in reshaping hematopoietic stem‑cell epigenetics, fostering pre‑leukemic clones and suggesting early anti‑inflammatory interventions could curb leukemogenesis. Infinimmune presented preclinical data for its anti‑IL‑22 monoclonal antibody IFX‑101, which markedly reduced atopic dermatitis symptoms in mice and demonstrated a 12‑day half‑life in primates, positioning it for a Phase I safety trial in Q4 2026.
Jiangsu and Shanghai Hengrui patented selective Nav1.8 blockers that show potent analgesic effects with minimal off‑target activity. New research links chronic inflammation in the bone‑marrow niche to epigenetic reprogramming of hematopoietic stem cells, suggesting early‑intervention strategies for leukemia prevention. Infinimmune...
Suzhou Spring‑Sea Bio‑Pharmaceuticals announced the discovery of a novel series of glucagon‑like peptide‑1 receptor (GLP‑1R) agonists that demonstrate high potency and prolonged half‑life in pre‑clinical models. The compounds show superior glucose‑lowering efficacy compared with existing market leaders and exhibit favorable...
Researchers at Jiangsu and Shanghai Hengrui have patented Nav1.8 blockers that deliver strong analgesic effects while sparing off‑target channels, opening a new avenue for chronic pain therapy. Parallel studies reveal that chronic inflammation can reprogram hematopoietic stem cells, driving early...
Vertex Pharmaceuticals has filed a patent covering a new series of orexin OX2‑receptor agonists, marking the company’s first public foray into sleep‑modulating therapeutics. The disclosed molecules feature distinct heterocyclic cores and enhanced blood‑brain barrier penetration, aiming for improved potency and...
Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that relieve neuropathic and inflammatory pain in rodents without impairing motor function, with filings in China and the United States and IND‑enabling work slated for later this year....
Biopharma X unveiled a next‑generation anti‑CD30 antibody‑drug conjugate that demonstrated superior efficacy and tolerability compared with the established therapy brentuximab vedotin. In preclinical models, the ADC achieved deeper tumor regressions and a broader therapeutic window, driven by an optimized linker...
Researchers have identified a novel Nrf2 activator that mitigates key pathological features of atopic dermatitis in preclinical studies. The compound suppresses oxidative stress and downregulates pro‑inflammatory cytokines, leading to restored skin barrier integrity in murine models. Data presented at the...
Researchers have identified a new class of liver receptor homolog‑1 (LRH‑1) antagonists that demonstrate potent antitumor activity in preclinical prostate cancer models. In mouse xenografts, oral administration of the compounds reduced tumor volume by up to 65% without notable adverse...
Boehringer Ingelheim has created a new obesity and liver health unit led by senior vice president Vani Manja, targeting a rapidly expanding GLP‑1 market that could reach 25 million U.S. patients by 2030. The company’s pipeline features the dual glucagon/GLP‑1 agonist...
A trio of European epidemiologists reaffirmed that the United States’ 2024 withdrawal from the World Health Organization satisfies the International Health Regulations’ criteria for a Public Health Emergency of International Concern (PHEIC). They cite their February 2025 LinkedIn analysis, which...
Sanofi reported mixed Phase 2 results for its bispecific antibody lunsekig. The drug achieved its primary and key secondary endpoints in moderate‑to‑severe asthma and chronic rhinitis with nasal polyps, showing reduced exacerbations, improved lung function and smaller polyps. Conversely, lunsekig failed...
Biogen has signed a collaboration and license agreement with Alloy Therapeutics to use the company’s AntiClastic antisense oligonucleotide (ASO) platform on multiple undisclosed targets. The deal provides Alloy with an upfront cash payment, additional milestone fees and tiered royalties on...
Pam Harter, a hospice patient in Napa, California, is campaigning to become the first hospice patient in space while using her journey to highlight the benefits of hospice care. Diagnosed with the rare genetic disorder pseudoxanthoma elasticum, she entered hospice...
On 1 April, NHS England launched the TPPSFS programme, a £250 million (£320 million) initiative that subsumes the existing Digital Transformation of Screening project and aims to overhaul patient, public and staff‑facing services. The plan outlines eight priority areas, including a full...
Gilead Sciences announced it will acquire Germany‑based Tubulis GmbH for up to $5 billion, adding the biotech’s antibody‑drug conjugate (ADC) platform to its portfolio. The deal follows Gilead’s recent $7.8 billion purchase of Arcellx and a $2 billion acquisition of Ouro Medicines, reflecting...
Gilead announced its third acquisition of 2026, agreeing to pay $3.15 billion upfront for Tubulis, a German startup that has built a next‑generation antibody‑drug conjugate (ADC) platform. The deal includes a contingent earn‑out of up to $1.85 billion tied to future milestones....
Kry Livi has teamed up with HA | Wisdom Wellbeing to embed its fast‑access digital GP service into the provider’s Employee Assistance Programme, extending coverage to more than 16 million people across the UK and Ireland and over 90,000 organisations. Users...
A cross‑sectional study of 4,042 German adults found that fewer daily social contacts are linked to higher loneliness, a relationship that holds for both healthy and depressed participants. The association is markedly stronger among the 1,221 respondents with a lifetime...
A California man pleaded guilty to submitting nearly $270 million in fraudulent Medi‑Cal claims over an 11‑month period, billing the state for expensive prescription drugs that were either unnecessary or never dispensed. The scheme leveraged a temporary suspension of prior‑authorization requirements,...
Evommune became one of only eleven biotech companies to go public in 2025, breaking a severe IPO drought that followed the 2021 funding boom. The firm’s phase 2a trial of its IL‑18 biologic EVO301 showed promising results in atopic dermatitis, sending...
Warrington Innovation Network’s Primary Care Network is deploying Aide Health’s AI‑driven platform across six GP surgeries, reaching roughly 55,000 patients. The service delivers daily, short‑form check‑ins to help people with COPD, obesity and hypertension manage medication, monitor symptoms and receive...
Weight‑loss drugs targeting the GLP‑1 pathway are reshaping consumer demand for smaller, nutrient‑dense portions, prompting food manufacturers to explore “GLP‑1 friendly” labeling. In the EU, such phrasing is classified as a health claim and, without an approved application, is unlikely...
A 16‑year longitudinal study of 793 middle‑aged adults found that higher vitamin D levels in their 30s‑40s were associated with lower tau protein accumulation later, a biomarker linked to Alzheimer’s disease. Participants with vitamin D above 30 ng/mL showed reduced tau...
NHS England reports steady progress toward a digital‑by‑default NHS, with most trusts now running electronic patient records (EPRs) and central data repositories. High‑performing trusts are 8% more productive per pound, achieve a 4% shorter length of stay, and meet referral...
Musgrove Park Hospital in Somerset has reopened its Nuclear Medicine department after a comprehensive refurbishment that includes a brand‑new SPECT/CT scanner. The state‑of‑the‑art equipment merges nuclear imaging with diagnostic‑quality CT, delivering high‑resolution 3‑D images for precise diagnosis and treatment planning....
MIT researchers unveiled BODHI, a “humble” AI framework that forces large language models to explicitly signal uncertainty in clinical diagnoses. The system implements six integrated steps and a two‑pass chain‑of‑thought prompting that separates internal reasoning from the clinician‑facing response. In...
Akeso presented Phase Ib/II data on its cadonilimab combination with anlotinib and docetaxel in patients whose advanced non‑small cell lung cancer (NSCLC) progressed after PD-(L)1 inhibitor therapy. At a median follow‑up of 21.5 months, the regimen achieved a 6‑month progression‑free...
BioNTech announced it will close its Singapore headquarters, a manufacturing site it purchased from Novartis in 2020. The Tuas Biomedical Park facility, which employs roughly 200 staff, will be shuttered as part of a comprehensive operational review. The decision reflects...
The National Institute for Health and Care Research has awarded Leeds Teaching Hospitals £1.5 million (about $1.9 million) to accelerate four priority projects, including AI‑driven imaging algorithms, a non‑invasive histotripsy platform for cancer therapy, a simulated surgical suite for greener operations, and...
President Trump’s FY 2027 budget proposes a $7.23 billion allocation for the FDA, a 3.2% increase over 2026, while the broader HHS budget shrinks by 12%. The agency plans to make the rare pediatric disease priority‑review voucher program permanent, averting an estimated...
Sanofi reported mixed phase 2 results for its bispecific antibody lunsekimig, which targets IL‑13 and TSLP. The drug met primary endpoints in the AIRCULES asthma trial and the DUET study for chronic rhinosinusitis with nasal polyps, showing reduced exacerbations and improved...
Sanofi announced mixed mid‑stage results for its bispecific nanobody aimed at treating multiple immune‑mediated diseases. The drug achieved its primary endpoints in Phase 2 trials for asthma and chronic rhinosinusitis with nasal polyps, demonstrating clinically meaningful improvements. Conversely, the same molecule...
Organogenesis completed a 170‑patient randomized trial of PuraPly AM, an antimicrobial collagen matrix, versus standard of care for non‑healing diabetic foot ulcers. The study met its primary endpoint, showing significantly higher wound‑closure rates at 12 weeks. PuraPly AM integrates cross‑linked...
Apnimed secured a senior secured credit facility of up to $150 million from HealthCare Royalty Partners to fund the commercial readiness and potential U.S. launch of AD109, an oral therapy for obstructive sleep apnea. The deal provides an initial $50 million at...
Paris‑based biotech Generare closed a €20 million Series A to expand its nature‑derived compound library. The company claims it uncovered more than 200 previously unknown microbial small molecules in 2025, outpacing the rest of the field combined. Generare’s platform scans microbial genomes,...
Merck’s experimental HIV‑prevention pill MK 8527 could be manufactured for less than $5 per patient annually, according to a recent cost‑analysis. The drug is in two late‑stage clinical trials that will report efficacy data in the second half of 2027. Earlier...
A 2026 study of 110 AIDS patients identified low body mass index, low CD4⁺ T‑lymphocyte count, and low serum albumin as independent nutritional risk factors. Using these three routinely measured variables, the authors built a nomogram that achieved an area...
A prospective study of 603 ICU patients found that bedside measurements of quadriceps muscle – both circumference and ultrasound thickness – independently predict 28‑day mortality. Higher quadriceps circumference (QC) and greater ultrasound‑derived thickness under minimal (QT‑min) and maximal (QT‑max) transducer...
Amgen’s Tepezza, the only FDA‑approved therapy for thyroid eye disease, generated about $1.9 billion in 2023 but its IV dosing schedule has limited broader adoption. The company has developed a subcutaneous formulation delivered twice weekly via a wearable injector, aiming to...
Researchers at Case Western Reserve University and University Hospitals have engineered a novel CAR‑T cell therapy, OSM CAR‑T, that targets oncostatin M receptors on osteosarcoma cells. Preclinical experiments demonstrated potent in‑vitro killing and significant tumor burden reduction in multiple mouse...
Silo Pharma’s shares surged 51.8% to $0.54 in pre‑market trading after the European Patent Office issued a Rule 71(3) communication indicating a likely grant of a patent for its novel 5‑HT4 receptor preventative therapy. The announcement sparked a broader pre‑market rally...
Dental billing software and AI tools have streamlined routine claim processing, but they fall short on complex cases that require nuanced judgment. Human specialists can interpret carrier‑specific rules, craft targeted appeals, and detect systemic denial patterns that automation misses. Over‑reliance...
A 2016 congressional law requiring providers to deliver complete medical records electronically took effect in 2021, giving patients instant access to raw test results. This transparency has sparked a new genre of social‑media videos where individuals broadcast their real‑time reactions...
Sovato has appointed former Intuitive executive Brian Miller as CEO to accelerate its telesurgery platform worldwide. Miller argues that surgeon shortages, geographic variability in outcomes, and proven remote‑surgery technology create a ripe market. Sovato’s strategy focuses on integrating with large...
Family physicians are increasingly adopting AI-powered notetaking tools that listen to patient conversations and generate visit summaries within seconds. Cleveland Clinic doctor Eric Boose reports that the technology lets him focus on face‑to‑face interaction, reduces charting time, and lets him...
Allergan Aesthetics presented new data at the 2026 AAD meeting linking the surge in GLP‑1 weight‑loss drug use to a growing demand for facial aesthetic treatments. A survey of U.S. clinicians showed that 52% of patients on GLP‑1 agonists express...
Researchers responded to feedback on their COPD admission risk score, noting that among six candidate predictors only diabetes remained statistically significant. The model, built on the Birmingham Lung Improvement Studies (BLISS) dataset, was externally validated in the ECLIPSE and CPRD...
Leukapheresis is emerging as a structural bottleneck as CAR‑T and other cell‑gene therapies expand beyond oncology into autoimmune, cardiovascular and respiratory diseases. The current model relies on a handful of academic centers, creating capacity constraints, geographic inequities, and variability in...
Resident doctors in England launched a six‑day strike, their 15th action over pay, prompting emergency cover and cancellation of some treatments. The NHS says 95% of appointments remain, while the government estimates the disruption costs £50 million daily, about £3 billion since...
